The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients - Trial NCT00911157
Access comprehensive clinical trial information for NCT00911157 through Pure Global AI's free database. This Phase 3 trial is sponsored by GlaxoSmithKline and is currently Completed. The study focuses on Thrombosis, Venous. Target enrollment is 39 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
GlaxoSmithKline
Timeline & Enrollment
Phase 3
Jun 01, 2008
Nov 01, 2009
Primary Outcome
Percentage of Participants With Recurrent or New Symptomatic Venous Thromboembolism (VTE)
Summary
The primary objective of this study is to evaluate the efficacy (as measured by the rate of
 recurrent symptomatic Venous Thromboembolism [VTE] (i.e., Pulmonary thromboembolism [PE] and
 Deep Vein Thrombosis [DVT])) and safety of GSK576428 as the initial treatment in subjects
 with acute symptomatic DVT in an open-label design.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT00911157
Non-Device Trial